Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663858 | 0.96 | PTGS2 (0.36) | PTGS2KCNH2CYSLTR2CYSLTR1PPARG | |
| SCHEMBL3656907 | 0.91 | PTGS2 (0.34) | PTGS2APP | |
| SCHEMBL3658303 | 0.85 | PPARG (0.36) | PTGS2PPARGPPARAPTPN1 | |
| SCHEMBL3656186 | 0.85 | APP (0.34) | PTGS2APP | |
| SCHEMBL3664058 | 0.84 | L3MBTL1 (0.35) | PTGS2PPARGPPARAPTPN1APP | |
| SCHEMBL3659801 | 0.83 | L3MBTL1 (0.37) | KCNH2PPARGPPARAPTPN1APP | |
| SCHEMBL3662361 | 0.81 | L3MBTL1 (0.35) | KCNH2PPARGPPARAPTPN1APP | |
| SCHEMBL3662868 | 0.80 | APP (0.35) | PTGS2APP | |
| SCHEMBL3761760 | 0.80 | PTGS2 (0.38) | PTGS2KCNH2PPARGPPARA | |
| SCHEMBL3661720 | 0.80 | PTPN1 (0.33) | PTGS2PPARGPPARAPTPN1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | PTGS2 3626/4885KCNH2 677/4885CYSLTR2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.